#USA #Philadelphia #HealthCONx #Carisma Therapeutics #Steven Kelly

Carisma Therapeutics to Attend HealthCONx Conference

Carisma Therapeutics Inc. (Nasdaq: CARM), a leading clinical-stage biopharmaceutical enterprise, is set to participate in the prestigious 7th Annual Evercore ISI HealthCONx Conference, scheduled to take place on December 5th, 2024. The event will feature a significant fireside chat with none other than Steven Kelly, the President and Chief Executive Officer of Carisma. The chat is expected to commence at 9:35 AM ET, offering insights into the company's innovative approaches and ongoing projects in immunotherapy.

The Evercore ISI HealthCONx Conference is known for bringing together key players in the health sector, providing a platform for discussion about the latest advancements and sectors of interest within the pharmaceutical and biotechnology landscapes. With an increasing focus on personalized medicine and targeted therapies, Carisma is positioning itself as a forerunner in these fields with its cutting-edge macrophage and monocyte cell engineering technology.

About Carisma Therapeutics

Founded with the mission of harnessing the body’s own immune resources to combat cancer and other serious health conditions, Carisma Therapeutics has developed a proprietary platform that focuses on engineered cells capable of enhancing both innate and adaptive immune responses. This technology not only aims to improve treatment efficacy but also seeks to minimize severe side effects that are often associated with traditional therapies.

Carisma’s headquarters is located in Philadelphia, PA, where it conducts research and clinical trials that aim to validate the potential of its innovative therapies. As part of its commitment to transparency and investor relations, the company will provide a live audio webcast of Steven Kelly's discussion, which will later be archived for public access on its Investor Relations webpage.

Engaging with investors and stakeholders at this conference allows Carisma to showcase its groundbreaking research and clinical progress, which continues to attract attention within the biopharmaceutical community. With various trials underway, the company is optimistic about the future of its therapies and the potential they hold for revolutionizing treatment for cancer patients.

For more details on its ongoing work and innovations, interested parties can visit Carisma’s official website.

As the biopharmaceutical industry evolves with rapid advancements, events such as the Evercore ISI HealthCONx Conference not only spotlight the achievements of companies like Carisma Therapeutics but also set the stage for future strategies in healthcare innovation.

Stay tuned for updates on Carisma's participation and key insights from the event as it approaches. The company's unique approach to immunotherapy is anticipated to significantly impact the landscape of cancer treatment and beyond, further establishing Carisma as a notable player in the industry.